Published DateClear

Start Date

End Date

Category

• Business1
• Products1

Organizations

• Bausch + Lomb67
• Eyes On Eyecare53
• Alcon, Inc.47
• American Optometric Association38
• Harrow31
• Glaukos28
• Regeneron25
• Topcon Healthcare25
• Aldeyra Therapeutics21
• Sight Sciences19

Tags

• Retina2
• AMD1
• DME1
• Eylea1
• Fda Approval1
• Acquisitions1
• Biosimilar1
• Diabetic Retinopathy1
• Geographic Atrophy1
• Injections1

• Organizations: Biogen✕

Clear all

Business

Biogen is purchasing Apellis

With an estimated price tag of $5.6 billion, the acquisition includes the FDA-approved SYFOVRE.

Products

FDA approves first interchangeable aflibercept biosimilars

Generic equivalents to Eylea demonstrate a comparable quality, safety, and efficacy profile for wet AMD, DME, RVO, and DR.